The complex challenge of chronic obstructive pulmonary disease

The Lancet Respiratory Medicine

Volumn 3, Issue 12, 2015, Pages 917-919

  Duffy, Sean ^a   Weir, Mark ^a   Criner, Gerard J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL; GLUCOCORTICOID; GLYCOPYRRONIUM BROMIDE; INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; ROFLUMILAST; TIOTROPIUM BROMIDE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE EXPRESSION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LUNG FUNCTION; NOTE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REWARD; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TH2 CELL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84961828044     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00480-4     Document Type: Note

References (10)

1. Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015, 373:111-122.
2. Wain LV, Shrine N, Miller S, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med 2015, 3:769-781.
3. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015, 191:758-766.
4. Steiling K, van den Berge M, Hijazi K, et al. A dynamic bronchial airway gene expression signature of COPD and lung function impairment. Am J Respir Crit Care Med 2013, 187:933-942.
5. Tilley AE, O'Connor TP, Hackett NR, et al. Biologic phenotyping of the human small airway epithelial response to cigarette smoking. PLoS One 2011, 6:e22798.
6. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009, 151:517-527.
7. Halpern SD, French D, Small DS, et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med 2015, 372:2108-2117.
8. Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 2015, 70:311-319.
9. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
10. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015, 385:857-866.